Aquestive Therapeutics, Inc. AQST Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s investing cash flow?
- Aquestive Therapeutics, Inc. (AQST) reported investing cash flow of -$52K in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Aquestive Therapeutics, Inc.'s investing cash flow increased by 61.5% year-over-year, from -$135K to -$52K.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s investing cash flow?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s investing cash flow has grown at a -11.4% compound annual growth rate (CAGR), from -$913K to -$562K.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.